Amylin Pharmaceuticals (Nasdaq:AMLN), Kendle International (Nasdaq:KNDL) and Sigma Designs (Nasdaq:SIGM) got hammered last week, falling from 13.07 percent to 25.38 percent in one day.
This is an all too familiar and distasteful feeling for investors in Amylin Pharmaceuticals. Back in October, they got crushed when Amylin lost almost half its market value after the FDA rejected its diabetes drug Bydureon, saying the drug needed more testing.
So yesterday, Amylin and partners Eli Lilly (NYSE:LLY) and Alkermes announced results from a new clinical trial against Novo Nordisk's (NYSE:NVO) Victoza (which weren't part of the regulatory process) and came up short. Apparently, way short. While the pharmaceutical still plans to resubmit its application to market Bydureon for the third time, investors aren't waiting around again.
Clinical research organization Kendle International sold off sharply yesterday over the big fourth-quarter loss it reported, reversing a year-ago profit, and it's down another 11% this morning.
Sigma's on board with Motorola Mobility (MMI), Cisco (Nasdaq:CSCO), and others, and Sigma-based boxes for IPTV solutions are expanding. There's no reason to think Sigma Designs won't be laughing at this plunge later.
Full Story
Showing posts with label Sigma Designs. Show all posts
Showing posts with label Sigma Designs. Show all posts
Monday, March 7, 2011
Thursday, December 2, 2010
Sigma Designs (NASDAQ:SIGM) Chip Demand Rising
Demand for televisions with chips from Sigma Designs (NASDAQ:SIGM) in them, along with an improving supply chain, resulted in the company beating estimates in the third quarter.
Going forward, BWS Financial said, "We are currently projecting a sequentially down quarter with revenue of approximately $71.1 million. The decline stemming from reduced IPTV installments during the end of the calendar year. Any hint of SIGM being able to maintain an EPS level of $1.30/$1.35 could be met with some buying opportunity."
Revenue for the quarter increased to $77.8 million, over twice the same quarter in 2009. Gross profit increased to 49.6 of sales, beating the 47.7 percent in the prior quarter, and the 45.3 percent in the same quarter last year.
With supply and demand in balance, it could be a catalyst going forward for Sigma.
They closed Wednesday at $12.12, gaining $0.12, or 1 percent.
Going forward, BWS Financial said, "We are currently projecting a sequentially down quarter with revenue of approximately $71.1 million. The decline stemming from reduced IPTV installments during the end of the calendar year. Any hint of SIGM being able to maintain an EPS level of $1.30/$1.35 could be met with some buying opportunity."
Revenue for the quarter increased to $77.8 million, over twice the same quarter in 2009. Gross profit increased to 49.6 of sales, beating the 47.7 percent in the prior quarter, and the 45.3 percent in the same quarter last year.
With supply and demand in balance, it could be a catalyst going forward for Sigma.
They closed Wednesday at $12.12, gaining $0.12, or 1 percent.
Subscribe to:
Posts (Atom)